ERBB2 and breast neoplasm: VeraTagTM technology, which utilizes a fluorescence-based dual antibody system, can be utilized to specifically and quantitatively measure protein-protein interactions [38], and is currently used in the commercially available HERmark® assay, which measures total HER2 and HER2-HER2 associations in FFPE breast tumors [39].